TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response.
Saraí G De Leon-RodríguezCristina Aguilar-FloresJulián A GajónÁngel Juárez-FloresAlejandra MantillaRaquel Gerson-CwilichJosé Fabián Martínez-HerreraDiana Alejandra Villegas-OsornoClaudia T Gutiérrez-QuirozSergio Buenaventura-CisnerosMario Alberto Sánchez-PrietoEdmundo Castelán-MaldonadoSamuel Rivera RiveraEzequiel M Fuentes-PananaLaura Cecilia Bonifaz-AlfonzoPublished in: Journal for immunotherapy of cancer (2024)
Our study supports the importance of TRM CD8 T cells and cDC1 in melanoma protection while also highlighting the existence of functionally distinctive TCF1+ and TCF1- TRM subsets, both crucial for melanoma control and CBI response.